Microbiology & Immunology

Recent Publications

• GEMMs Are a Gem When it Comes to Defining the Role of HIF2α in Mucinous Cystic Neoplasms.

  (Boyle KA, Dwinell MB.) Cell Mol Gastroenterol Hepatol. 2018;5(2):165-166.

• Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models.

  (Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA.) BMC Cancer. 2018 03 27;18(1):335.

• Corrigendum to 'A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds' [REDOX 14C (2017) 316-327].

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 06;16:426-427.

• A review of the basics of mitochondrial bioenergetics, metabolism, and related signaling pathways in cancer cells: Therapeutic targeting of tumor mitochondria with lipophilic cationic compounds.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Lopez M, Joseph J, Zielonka J, Dwinell MB.) Redox Biol. 2018 04;14:316-327.

• Differences in Sulfotyrosine Binding amongst CXCR1 and CXCR2 Chemokine Ligands.

  (Moussouras NA, Getschman AE, Lackner ER, Veldkamp CT, Dwinell MB, Volkman BF.) Int J Mol Sci. 2017 Sep 03;18(9).

• CCR7 Sulfotyrosine Enhances CCL21 Binding.

  (Phillips AJ, Taleski D, Koplinski CA, Getschman AE, Moussouras NA, Richard AM, Peterson FC, Dwinell MB, Volkman BF, Payne RJ, Veldkamp CT.) Int J Mol Sci. 2017 Aug 25;18(9).

• Modified Metformin as a More Potent Anticancer Drug: Mitochondrial Inhibition, Redox Signaling, Antiproliferative Effects and Future EPR Studies.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell MB.) Cell Biochem Biophys. 2017 Dec;75(3-4):311-317.

• Mitochondria-targeted metformins: anti-tumour and redox signalling mechanisms.

  (Kalyanaraman B, Cheng G, Hardy M, Ouari O, Sikora A, Zielonka J, Dwinell M.) Interface Focus. 2017 Apr 06;7(2):20160109.

• Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

  (Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.) Sci Signal. 2017 Mar 21;10(471).

• Cancer cell chemokines direct chemotaxis of activated stellate cells in pancreatic ductal adenocarcinoma.

  (Roy I, Boyle KA, Vonderhaar EP, Zimmerman NP, Gorse E, Mackinnon AC, Hwang RF, Franco-Barraza J, Cukierman E, Tsai S, Evans DB, Dwinell MB.) Lab Invest. 2017 03;97(3):302-317.

• Exploiting agonist biased signaling of chemokines to target cancer.

  (Roy I, Getschman AE, Volkman BF, Dwinell MB.) Mol Carcinog. 2017 03;56(3):804-813.

• E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells.

  (Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA.) Oncotarget. 2016 Jul 12;7(28):43363-43375.

• Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells.

  (Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, Dwinell MB, Kalyanaraman B.) Cancer Res. 2016 07 01;76(13):3904-15.

• Generation and characterization of mice harboring a conditional CXCL12 allele.

  (Hillmer RE, Boisvert JP, Cucciare MJ, Dwinell MB, Joksimovic M.) Int J Dev Biol. 2015;59(4-6):205-9.

• Pancreatic Cancer Cell Migration and Metastasis Is Regulated by Chemokine-Biased Agonism and Bioenergetic Signaling.

  (Roy I, McAllister DM, Gorse E, Dixon K, Piper CT, Zimmerman NP, Getschman AE, Tsai S, Engle DD, Evans DB, Volkman BF, Kalyanaraman B, Dwinell MB.) Cancer Res. 2015 Sep 01;75(17):3529-42.